Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02046395 · ClinicalTrials.gov registry record · Phase 4
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by Tulane University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT02046395 is a Phase 4 study that has completed, run by Tulane University School of Medicine. The registered enrollment target is 28 participants.
The verdict
NCT02046395, a Phase 4 study, has completed, sponsored by Tulane University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to study the effect of blocking the renin angiotensin system on urinary free light chain excretion as compared to urine microalbumin creatinine ratio in subjects with type 2 diabetes. The long term goal is to assess urinary free-light chains as a biomarker of earlier detection of kidney function impairment in subjects with diabetes mellitus.
Interventions
- DRUG amlodipine, hydralazine, terazosin or hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02046395
The ClinicalTrials.gov registry entry for NCT02046395 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which amlodipine, hydralazine, terazosin or hydrochlorothiazide is the first listed.
NCT02046395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02046395 about?
NCT02046395 is a clinical study titled "Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to study the effect of blocking the renin angiotensin system on urinary free light chain excretion as compared to urine microalbumin creatinine ratio in subjects with type 2 diabetes. The long term goal is to assess urinary free-light chains as a biomarker of earlier det...
What is the current status of trial NCT02046395?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2012-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02046395?
The interventions under investigation include: amlodipine, hydralazine, terazosin or hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT02046395?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.